Expression of DeltaNp73 is a molecular marker for adverse outcome in neuroblastoma patients - PubMed (original) (raw)
Expression of DeltaNp73 is a molecular marker for adverse outcome in neuroblastoma patients
I Casciano et al. Cell Death Differ. 2002 Mar.
Abstract
The p73 gene is a p53 homologue which induces apoptosis and inhibits cell proliferation. Although p73 maps at 1p36.3 and is frequently deleted in neuroblastoma (NB), it does not act as a classic oncosuppressor gene. In developing sympathetic neurons of mice, p73 is predominantly expressed as a truncated anti-apoptotic isoform (DeltaNp73), which antagonizes both p53 and the full-length p73 protein (TAp73). This suggests that p73 may be part of a complex tumor-control mechanism. To determine the role of DeltaNp73 in NB we analyzed the pattern of expression of this gene in vivo and evaluated the prognostic significance of its expression. Our results indicate that DeltaNp73 expression is associated with reduced apoptosis in a NB tumor tissue. Expression of this variant in NB patients significantly correlates with age at diagnosis and VMA urinary excretion. Moreover it is strongly associated with reduced survival (HR=7.93; P<0.001) and progression-free survival (HR=5.3; P<0.001) and its role in predicting a poorer outcome is independent from age, primary tumor site, stage and MYCN amplification (OS: HR=5.24, P=0.012; PFS: HR=4.36, P=0.005). In conclusion our data seem to indicate that DeltaNp73 is a crucial gene in neuroblastoma pathogenesis.
Comment in
- The two faces of p73.
Grob TJ, Fey MF, Tobler A. Grob TJ, et al. Cell Death Differ. 2002 Mar;9(3):229-30. doi: 10.1038/sj.cdd.4401018. Cell Death Differ. 2002. PMID: 11859403 No abstract available.
Similar articles
- Biological and clinical role of p73 in neuroblastoma.
Romani M, Tonini GP, Banelli B, Allemanni G, Mazzocco K, Scaruffi P, Boni L, Ponzoni M, Pagnan G, Raffaghello L, Ferrini S, Croce M, Casciano I. Romani M, et al. Cancer Lett. 2003 Jul 18;197(1-2):111-7. doi: 10.1016/s0304-3835(03)00092-2. Cancer Lett. 2003. PMID: 12880969 Review. - DeltaNp73 antisense activates PUMA and induces apoptosis in neuroblastoma cells.
Simões-Wüst AP, Sigrist B, Belyanskaya L, Hopkins Donaldson S, Stahel RA, Zangemeister-Wittke U. Simões-Wüst AP, et al. J Neurooncol. 2005 Mar;72(1):29-34. doi: 10.1007/s11060-004-3118-8. J Neurooncol. 2005. PMID: 15803372 - Spatiotemporal switch from DeltaNp73 to TAp73 isoforms during nephrogenesis: impact on differentiation gene expression.
Saifudeen Z, Diavolitsis V, Stefkova J, Dipp S, Fan H, El-Dahr SS. Saifudeen Z, et al. J Biol Chem. 2005 Jun 17;280(24):23094-102. doi: 10.1074/jbc.M414575200. Epub 2005 Apr 1. J Biol Chem. 2005. PMID: 15805112 - Negative autoregulation of p73 and p53 by DeltaNp73 in regulating differentiation and survival of human neuroblastoma cells.
Nakagawa T, Takahashi M, Ozaki T, Watanabe K, Hayashi S, Hosoda M, Todo S, Nakagawara A. Nakagawa T, et al. Cancer Lett. 2003 Jul 18;197(1-2):105-9. doi: 10.1016/s0304-3835(03)00090-9. Cancer Lett. 2003. PMID: 12880968 Review. - p73alpha isoforms drive opposite transcriptional and post-transcriptional regulation of MYCN expression in neuroblastoma cells.
Horvilleur E, Bauer M, Goldschneider D, Mergui X, de la Motte A, Bénard J, Douc-Rasy S, Cappellen D. Horvilleur E, et al. Nucleic Acids Res. 2008 Aug;36(13):4222-32. doi: 10.1093/nar/gkn394. Epub 2008 Jun 25. Nucleic Acids Res. 2008. PMID: 18583365 Free PMC article.
Cited by
- The RUNX Family Defines Trk Phenotype and Aggressiveness of Human Neuroblastoma through Regulation of p53 and MYCN.
Ando K, Nakagawara A. Ando K, et al. Cells. 2023 Feb 8;12(4):544. doi: 10.3390/cells12040544. Cells. 2023. PMID: 36831211 Free PMC article. Review. - Deciphering the Role of p53 and TAp73 in Neuroblastoma: From Pathogenesis to Treatment.
Almeida J, Mota I, Skoda J, Sousa E, Cidade H, Saraiva L. Almeida J, et al. Cancers (Basel). 2022 Dec 16;14(24):6212. doi: 10.3390/cancers14246212. Cancers (Basel). 2022. PMID: 36551697 Free PMC article. Review. - Requirement for TP73 and genetic alterations originating from its intragenic super-enhancer in adult T-cell leukemia.
Ong JZL, Yokomori R, Wong RWJ, Tan TK, Ueda R, Ishida T, Iida S, Sanda T. Ong JZL, et al. Leukemia. 2022 Sep;36(9):2293-2305. doi: 10.1038/s41375-022-01655-5. Epub 2022 Jul 30. Leukemia. 2022. PMID: 35908104 - Anti-cancer therapy is associated with long-term epigenomic changes in childhood cancer survivors.
Robinson N, Casement J, Gunter MJ, Huybrechts I, Agudo A, Barranco MR, Eichelmann F, Johnson T, Kaaks R, Pala V, Panico S, Sandanger TM, Schultze MB, Travis RC, Tumino R, Vineis P, Weiderpass E, Skinner R, Sharp L, McKay JA, Strathdee G. Robinson N, et al. Br J Cancer. 2022 Jul;127(2):288-300. doi: 10.1038/s41416-022-01792-9. Epub 2022 Mar 30. Br J Cancer. 2022. PMID: 35354948 Free PMC article. - Dual Role of p73 in Cancer Microenvironment and DNA Damage Response.
Rozenberg JM, Zvereva S, Dalina A, Blatov I, Zubarev I, Luppov D, Bessmertnyi A, Romanishin A, Alsoulaiman L, Kumeiko V, Kagansky A, Melino G, Barlev NA. Rozenberg JM, et al. Cells. 2021 Dec 13;10(12):3516. doi: 10.3390/cells10123516. Cells. 2021. PMID: 34944027 Free PMC article. Review.
Publication types
MeSH terms
Substances
LinkOut - more resources
Full Text Sources
Other Literature Sources
Medical
Molecular Biology Databases
Research Materials
Miscellaneous